Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma

Por Zhang, Mengxian, Lahn, Michael, Huber, Peter E.
Publicado em 2012

Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?

Por Saleem, Azeem, Murphy, Philip, Plisson, Christophe, Lahn, Michael
Publicado em 2014

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

Por Maier, Armin, Peille, Anne-Lise, Vuaroqueaux, Vincent, Lahn, Michael
Publicado no Cell Oncol (Dordr) (2015)

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

Por Shults, Keith, Flye, Leanne, Green, Lisa, Daly, Thomas, Manro, Jason R, Lahn, Michael
Publicado em 2009

Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide

Por Callies, Sophie, André, Valérie, Patel, Bharvin, Waters, David, Francis, Paul, Burgess, Michael, Lahn, Michael
Publicado em 2011

Role of gammadelta T cells in protecting normal airway function

Por Gelfand Erwin W, O'Brien Rebecca L, Kanehiro Arihiko, Takeda Katsuyuki, Lahn Michael, Born Willi K
Publicado em 2000-11-01

Role of gammadelta T cells in protecting normal airway function

Por Born, Willi K, Lahn, Michael, Takeda, Katsuyuki, Kanehiro, Arihiko, O'Brien, Rebecca L, Gelfand, Erwin W
Publicado em 2000

Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

Por Li, Shuyu, Phong, Mark, Lahn, Michael, Brail, Leslie, Sutton, Susan, Lin, Boris K, Thornton, Donald, Liao, Birong
Publicado em 2007

Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue

Por Wortinger, Mark A, Foley, Joseph W, Larocque, Patrick, Witcher, Derrick R, Lahn, Michael, Jakubowski, Joseph A, Glasebrook, Andrew, Song, Ho Yeong
Publicado em 2003

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Por O’Brien, Peter J, Ramanathan, Rajeev, Yingling, Jonathan M, Baselga, Jose, Rothenberg, Mace L, Carducci, Michael, Daly, Thomas, Adcock, Dorothy, Lahn, Michael
Publicado em 2008

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Por Gueorguieva, Ivelina, Cleverly, Ann L, Stauber, Anja, Pillay, N Sada, Rodon, Jordi A, Miles, Colin P, Yingling, Jonathan M, Lahn, Michael M
Publicado em 2014

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

Por Girvan, Allicia C, Carter, Gebra C, Li, Li, Kaltenboeck, Anna, Ivanova, Jasmina, Koh, Maria, Stevens, Jessi, Hayes-Larson, Eleanor, Lahn, Michael M
Publicado no Drugs Context (2015)

Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY215729...

Por SEPULVEDA-SANCHEZ, JUAN, RAMOS, ANA, HILARIO, AMAYA, DE VELASCO, GUILLERMO, CASTELLANO, DANIEL, GARCIA DE LA TORRE, MARTA, RODON, JORDI, LAHN, MICHAEL F.
Publicado no Oncol Lett (2015)

Trimodal Glioblastoma Treatment Consisting of Concurrent Radiotherapy, Temozolomide, and the Novel TGF-β Receptor I Kinase Inhibitor LY2109761

Por Zhang, Mengxian, Herion, Tobias W, Timke, Carmen, Han, Na, Hauser, Kai, Weber, Klaus J, Peschke, Peter, Wirkner, Ute, Lahn, Michael, Huber, Peter E
Publicado em 2011

Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relap...

Por Erba, Harry P., Sayar, Hamid, Juckett, Mark, Lahn, Michael, Andre, Valerie, Callies, Sophie, Schmidt, Shelly, Kadam, Sunil, Brandt, John T., Van Bockstaele, Dirk, Andreeff, Michael
Publicado em 2013

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Por Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Azaro, Analia, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Miles, Colin, Lahn, Michael M, Mitchell, Malcolm I, Rodon, Jordi
Publicado no Drugs Context (2016)

In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography

Por Pollok, Karen E., Lahn, Michael, Enas, Nathan, McNulty, Ann, Graff, Jeremy, Cai, Shanbao, Hartwell, Jennifer R., Ernstberger, Aaron, Thornton, Donald, Brail, Les, Hutchins, Gary
Publicado em 2009

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

Por COHN, ALLEN, LAHN, MICHAEL M., WILLIAMS, KRISTEN E., CLEVERLY, ANN L., PITOU, CELINE, KADAM, SUNIL K., FARMEN, MARK W., DESAIAH, DURISALA, RAJU, ROBERT, CONKLING, PAUL, RICHARDS, DONALD
Publicado em 2014

MHC class I-dependent Vγ4(+) pulmonary T cells regulate αβ T cell-independent airway responsiveness

Por Lahn, Michael, Kanehiro, Arihiko, Takeda, Katsuyuki, Terry, Jennifer, Hahn, Youn-Soo, Aydintug, M. Kemal, Konowal, Anatole, Ikuta, Koichi, O'Brien, Rebecca L., Gelfand, Erwin W., Born, Willi K.
Publicado em 2002

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Por Saleem, Azeem, Matthews, Julian C., Ranson, Malcolm, Callies, Sophie, André, Valérie, Lahn, Michael, Dickinson, Claire, Prenant, Christian, Brown, Gavin, McMahon, Adam, Talbot, Denis C., Jones, Terry, Price, Patricia M.
Publicado em 2011